NCT06272734招募中不适用
Reprieve System for the Treatment of Subjects With Acute Decompensated Heart Failure Pilot Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Functional Device Success
研究概览
简要总结
The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema/swelling) AND 1 sign (peripheral edema, ascites, jugular venous distension, pulmonary vascular congestion on chest radiography)
- •≥10 lb. (4.5 kg) above dry weight either by historical weights or as estimated by health care provider.
- •Patients ≥ 18 years of age able to provide informed consent and comply with study procedures.
排除标准
- •Inability to place Foley catheter or IV catheter or other urologic issues that would predispose the patient to a high rate of urogenital trauma or infection with catheter placement.
- •Hemodynamic instability as defined by any of the following: systolic blood pressure <90 mmHg, use of vasopressors, use of IV inotropes to treat hypotension (systolic blood pressure <90 mm Hg) or suspected/confirmed low cardiac output/shock, mechanical circulatory support, uncontrolled arrhythmias, active severe bleeding, or confirmed or suspected cardiogenic shock. Note: In the absence of the above conditions, use of inotropes to augment diuresis is permitted.
- •Dyspnea due primarily to non-cardiac causes (e.g., severe chronic obstructive pulmonary disease or pneumonia).
- •Acute infection with evidence of systemic involvement (e.g., clinically suspected infection with fever or elevated serum white blood cell count).
- •Estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m2 calculated using the MDRD equation or current use of renal replacement therapy (RRT).
- •Significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, known severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment (within previous week), or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated.
- •Inability to follow instructions or comply with follow-up procedures.
- •Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.
- •Severe baseline electrolyte abnormalities (e.g., serum potassium <3.0 mEq/L or magnesium <1.3 mEq/L). Note: These are based on baseline/screening labs. Subjects whose electrolyte levels are repleted cannot be reassessed for inclusion in the trial.
- •Serum sodium <135 mmol/L or history of severe hyponatremia
- •Poorly controlled diabetes
- •Enrollment in another interventional trial during the index hospitalization
- •Life expectancy less than 3 months
- •Women who are pregnant or intend to become pregnant.
研究组 & 干预措施
Reprieve System
Experimental
Subjects will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
干预措施: Reprieve System (Device)
结局指标
主要结局
Functional Device Success
时间窗: Over the 72-hours maximum duration of therapy.
Defined as the device's ability to perform its intended function as specified in the study protocol without any device-related adverse events or malfunctions as determined by the treating physician.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Evaluation of Desensitization Protocols in Reduction of Dentin HypersensitivityHypersensitivity DentinDentin SensitivityDentin HypersensitivityDentine HypersensitivityNCT03076944Federal University of Uberlandia32
招募中
早期 1 期
RELIEF OF PSYCHOEMOTIONAL STRESS USING XENON SEDATIONAnesthesiaXenonPsychological StressAnxietyNCT06080100The S.N. Fyodorov Eye Microsurgery State Institution140
已完成
2 期
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiaChronic Myeloid LeukaemiaNCT01804985University of Liverpool174
Unknown
不适用
A Subjective Observational Study of Patients Using Medicated Footbath/Footwash Treatment in Podiatry CareToenail Fungal InfectionAbscessPitted KeratolysisCellulitisDiabetic Foot UlcerNCT03781024Data Collection Analysis Business Management5,000
Unknown
不适用
Effect of Myofascial Release on Dysphagia in Stroke SurvivorsDysphagiaNCT06256848Zeng Changhao80